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Abstract 
Thermo-gelling injectable nanogels, with no burst release of loaded drug, were prepared 
by a simple route by combining self assembled nanocapsules of amphiphilically modified 
chitosan with glycerophosphate di-sodium salt and glycerol. The potential as a depot drug 
delivery system was demonstrated in vivo through the therapeutic effect of ethosuximide 
(ESM) loaded nanogels, suppressing spike wave discharges (SWDs) in Long Evan rat model. 
Simultaneously clearance of gels from the site of administration was monitored non-
invasively using MRI. The gel structure was characterized using TEM and SEM, confirming 
the gels to be an assembly of nanocapsules and using two-photon microscopy to visualize the 
network structure. In vitro drug release studies using ESM revealed that the nanogels 
exhibited extended, mostly Fickian release. Finally, all investigated formulations displayed 
excellent cytotoxicity data determined by MTT assay using human retinal pigmented 
epithelium cells. All presented properties are highly desirable for injectable depot gels for 
drug delivery. 
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1. INTRODUCTION 
In this study we set out to prepare chitosan based injectable drug loaded hydrogels 
without burst release, where a gel-network and drug encapsulation could be achieved using a 
single modified chitosan component, enabling extremely simple preparation procedure. This 
is of relevance as thermo-gelling formulations can be easily administrated to provide 
sustained systemic or local therapeutic effect when loaded with drugs or [1-4], but with burst 
release of a fraction of loaded drug being a commonly observed problem [5]. In addition, drug 
release of small hydrophilic molecules is often completed in less than 24 h [6]. The concept of 
solving this problem by encapsulating the drug into carriers subsequently embedded in the 
thermo-gelling matrix has been successful demonstrated previously [4, 6, 7]. However, to the 
authors’ knowledge all previous studies involve different components and preparation steps 
for the drug loading into nanocarriers and preparation of the thermo-gelling solution, 
respectively. 
When designing an injectable medical hydrogel the following requirements need 
considered and met for an ideal performance of the formulation, as stated by [8]: (1) a sol-to-
gel transition before and after injection into the sites of injury, (2) a biodegradable or 
gradually dissolving character, (3) both the hydrogel and the degradation products should be 
biocompatible, and (4) the gel should present desirable properties for the intended application, 
for instance, sustained release profile for drug delivery systems, or cell adhesive capabilities 
for tissue engineering.  
Chitosan (CS) is a polysaccharide which has been widely studied for use in biomedical 
applications as it presents desirable properties such as: biocompatibility, biodegradation, 
bioadhesivity, anti-bacterial effects and no toxicity [9-12].  
One common and straight forward approach to achieve CS solutions with thermo-
induced gelling is to include polyol salts such as; disodium-, ammonium hydrogen-, glycerol-, 
sorbitol-, fructose- or glucose-phosphate salts. These transform purely pH-dependent chitosan 
solutions into temperature-controlled pH-dependent chitosan solutions [2, 13-17]. Such 
solutions are typically liquids at low temperatures, but form gels at elevated temperatures, 
making them suitable as injectable in vivo gelling systems.  
Recently, chitosan based nanoscale drug-carriers formed from a new type of amphiphilic 
chitosan, namely carboxymethyl-hexanoyl chitosan (CHC) was successfully synthesized in 
this lab. Native chitosan was modified by partial substitution with hydrophilic carboxymethyl 
groups to increase the solubility of the chitosan polysaccharide chain in water and by partial 
substitution with hydrophobic hexanoyl groups to increase the amphiphilic character [18]. 
The CHC demonstrated self-assembly into nanocapsules about 200 nm in size in aqueous 
environment, and the capsules demonstrated good drug loading properties [18-20]. In a 
previous study, we demonstrated extremely slow release of hydrophobic drug from such CHC 
nanocarriers embedded in a macroscopic calcium alginate gel [21]. Based on those earlier 
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findings and the previously mentioned reports on preparation of thermo-gelling chitosan 
solutions using polyol salts, it was investigated if CHC could be used both to encapsulate 
drug, minimizing burst release, and to form a thermo-gelling network in the presence of a 
polyol salt. Such a formulation would allow for extremely easy sample preparation and 
because of the previously reported low cytotoxicity and host irritation of CHC it would hold 
great potential as an injectable drug depot platform [21, 22]. 
Indeed, when CHC nanocapsules in water were mixed with glycerol and sodium β-
glycerophosphate (β-GP) thermo-gelling solutions were formed. The formed CHC hydrogels 
were characterized with regard to; gelation time, rheological properties and structure using 
two-photon microscopy (TPM), SEM and TEM. The in vitro drug release from the formed 
gels was investigated using the highly water-soluble drug Ethosuximide (ESM). Cell 
cytotoxicity was investigated using a MTT assay. Finally, the feasibility of the CHC hydrogels 
as an injectable depot drug delivery system was demonstrated through the successful 
suppression of spike wave discharges (SWDs) in rats, combined with in vivo magnetic 
resonance imaging (MRI) of hydrogel clearance from the site of injection.  
2. METHODS 
2.1. Materials 
Carboxymethyl hexanoyl Chitosan (CHC), M.W. = 150000 g/mol and viscosity = 2500-
3500 cP (4 % solution),was bought from Advanced Delivery Technology Inc., Hsinchu, 
Taiwan under the name AC-SAC (nanocarrier), and its chemical identity was confirmed to be 
similar to previously reported CHC [18] using NMR (supplementary material Fig. S1). 
Glycerol, Ethosuximide (ESM), Pyrene and chemicals to prepare simulated body fluid (SBF); 
NaCl, NaHCO3, KCl, K2HPO4, MgCl2, HCl, CaCl2, Na2SO4, (CH2OH)3CNH2 were bought 
from Sigma-Aldrich. β-glycerol phosphate disodium salt hydrate (β-GP) was bought from 
Merck. Genipin was purchased from Challenge Bioproducts Co., Taiwan. 
2.2. Preparation of CHC thermo-gelling solutions 
Solutions with thermally induced sol-gel transition were prepared as follows: 1-3g (x) of 
CHC powder was dissolved in 100 ml distilled water (DW), the solution was then cooled in 
an ice bath. Subsequently, 0.5, 1 or 1.5 g (y) β-GP was dissolved in 9 ml of the CHC solution 
under stirring on ice. After mixing, 0-1 ml (z) glycerol + DW (total volume 1 ml) was 
dropped into 9 ml of the CHC/β-GP solution in ice bath to prepare 10 ml CHC-β-GP-glycerol 
hybrid solution. The samples were named accordingly Cx-βy-Gz. See supplementary material 
Table S1 for amounts used and sample naming. 
2.3. Gelation time and rheological analysis 
The time required at 37 
○
C to form a gel (designated as gelation time) was determined 
using a vial tilting method, where no flow within 1 minute of inverting the vial was the 
criterion for gel state [23, 24] 
Rheological properties of samples were monitored when pre-gelling solution was moved 
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from 4 to 37 
○
C using an ARES rheometer (Rheometric Scientific, Piscataway, NJ) ) fitted 
with a cone-plate tool, at a frequency of 10 rad / s and a strain of 1 %. The diameter of the 
plate was 25 mm. The force and displacement were recorded, and the dynamic storage (G’) 
and loss modulus (G”) were determined as functions of time. 
2.4. Morphological characterization of CHC nanogels 
Morphological evaluation of formed and subsequently dried or freeze-dried CHC gels 
was performed by transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM), respectively. The phase distribution in wet nanogels was analysed using 
two-photon microscopy (TPM) analysis of gel formed from CHC nanocarriers that were 
loaded with pyrene (10
-4
 M) as previously described [20]. The structure of eroded gel 
fragments was determined by SEM analysis nanogel fragments released after submersion in 
DW for one day (see supplementary material for details). 
2.5. In vitro drug release 
In vitro release studies in SBF were conducted on nanogels loaded with 0.1 g of the 
antiepileptic drug ethosuximide (ESM), crosslinked with genipin (100ppm) [25] to eliminate 
the effect of gel disintegration (see supplementary material for details).  
2.6. In vivo studies  
In vivo therapeutic effect of ESM released from implanted CHC nanogels was evaluated 
as follows. ESM loaded nanogels were subcutaneously injected into five Long Evan rats (300 
g, National Laboratory Animal Centre, Taiwan) which spontaneously present spike-wave 
discharges (SWDs) [26, 27]. The SWDs of Long Evan rats have been suggested to be an 
absence like seizure activity that is known to be suppressed by the antiepileptic drug ESM 
[26, 28, 29]. An electrophysiological method to record spike-wave discharges (SWDs) was 
used to evaluate the therapeutic effects of ESM released from the implanted CHC nanogels. 
Furthermore, magnetic resonance imaging (MRI) was noninvasively performed to investigate 
the clearance, of implanted CHC nanogels in vivo. Animal experiments and treatment of test 
animals were performed according to institutional ethical guidelines. Approval for the animal 
experiments was obtained from the Animal Research Committee of National Chiao-Tung 
University and National Taiwan University (see supplementary material for details). 
2.7. Cell culture cytotoxicity  
Different formulations of nanogels were investigated with regard to cytotoxicity by an 
MTT cell proliferation assay using ARPE-19 cells (see supplementary material for details). 
2.8 Statistical analysis 
For evaluation of in vivo therapeutic effect repeated measures analysis of variance 
(ANOVA) was used. Differences with p values of less than 0.05 were considered statistically 
significant. All statistical analyses were performed using SPSS (Statistical Package for the 
Social Sciences, version 10.0; SPSS, Chicago, IL, USA) for Windows. Other data are when 
applicable reported as mean ± SD, with number of replicates indicated. 
5 
 
3. RESULTS 
3.1. Gelation of the CHC hydrogels 
CHC self-assembles into nanocapsules in aqueous environment. At acidic to neutral pH 
the nanocapsules carry positive charges on their shell, derived from the protonation of amino 
groups. Here β-GP was used to neutralize the positive charge and reduce repulsive force 
between CHC nanocapsules at elevated temperatures, giving rise to a sol-gel transition with 
increased temperature. Furthermore, glycerol was added to provide increased gel strength, 
based on our previous experiences. Fig. 1a shows the concept of CHC nanogel preparation. 
The CHC pre-gelling solution is virtually a viscous liquid at low temperature, i.e. 4 - 10 
○
C, which exhibits flow under its own weight. However, the solution formed a gel within 
reasonable time when exposed to 37 
○
C or above, as demonstrated in Fig. 1b. 
The gelation time of different formulations when pre-gelling solution was moved from 4 to 37 
○
C was determined using the vial tilting method, see supplementary material Table S1. It was 
found that β-GP was a prerequisite for thermally induced gelling. Furthermore, a considerable 
reduction in the gelation time was observed for all formulations with increasing CHC content. 
The gelation time also decreased with increased addition of both β-GP and glycerol. No 
gelation was observed after 24 h for the samples with the lowest CHC content and no 
glycerol, irrespectively of β-GP content. The longest observed gelation times were > 1 h, 
while the shortest observed gelation time was about 150 s for the sample with the highest 
investigated CHC, β-GP and glycerol contents (C3-β15-G10). 
Rheological analysis revealed that initially the loss modulus G’’ was larger than the 
storage modulus G’, often taken as a criterion for a liquid. However, during the thermally 
induced gelation G’ increased more rapidly than G’’, so that a crossover point was observed 
(supplementary material Fig. S3). Such a crossover is often taken as a sign of gelation and the 
observed crossover-times were in reasonable agreement with the gelation times determined 
using the vial tilting method. 
3.2. Structure of the CHC hydrogels 
TEM analysis of dried gel revealed that the nanogel was composed of numerous 
nanocapsules Fig. 2a. The diameters observed in TEM was about 50 - 200 nm, which is 
similar to previous observations [19]. 
SEM analysis of freeze dried gel samples revealed structures interpreted as capsules 
having sizes ranging from about 100 nm to 500 nm (Fig. 2b). The fact that the observed sizes 
are larger than those observed using TEM is most likely due to swelling of the particles in 
solution. It is important to point out that CHC is in fact a minority component in the gels, the 
theoretical concentration per dry mass of the freeze dried samples ranged from about 35 % to 
14 % and the CHC concentration per volume would be as low as about 2 %. Thus major part 
of the samples would not be nanocapsules even if all CHC was present in that form. 
Furthermore, there is the possibility that some CHC existed as free polymer chains rather than 
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capsules and there was a big risk that any capsule structures present would be destroyed 
during the freeze drying process. Any material other than nanocapsules present in the samples 
would make the detection of nanocapsules difficult due to them being covered by the layer-
like structures formed during freeze-drying. The fact that nanocapsules could be observed 
after freeze-drying, despite the complicating factors discussed above, clearly indicates the 
presence of nanocapsules in the formed gels. From the TEM and SEM results it is concluded 
that CHC did exist as nanocapsules in the formed gels. 
To get an indication on the structure of the formed network, nanogel loaded with the 
hydrophobic fluorescent substance pyrene was analysed using TPM. Pyrene would mainly be 
located in the hydrophobic domains of CHC, thus the acquired images reflects the formed 
CHC network. The TPM-analysis revealed that the nanogel was composed of a continuous 
network, with phase domains having sizes in the micrometer range (Fig. 2c). 
It was observed that the nanogels disintegrated upon submersion in DW or SBF 
(Supplementary material Fig. S4). SEM analysis of fragments released from the bulk CHC gel 
during submersion in DW revealed that the gels disintegrated through the released of particles 
having sizes of several hundreds of nanometres (Fig. 2d), where the released particles were 
composed of an assembly of smaller objects. 
3.3. In vitro drug release 
Given the observation that the CHC nanogels disintegrated into nano-sized fragments in 
release media, a small amount of genipin was added to crosslink and thus stabilize the 
nanogels prior to in vitro release studies, this to eliminate any influence from gel erosion 
(disintegration) on the release profiles and release kinetics. The addition of genipin did not 
significantly influence the initial (1-2) days release from the gels (supplementary material Fig. 
S4). CHC nanogels loaded with 10 mg / ml of the hydrophilic antiepileptic drug ethosuximide 
(ESM) were prepared using different amounts of β-GP and glycerol in the pre-gelling 
solutions. As seen in Fig. 3, gels prepared without glycerol and with low amounts of β-GP 
displayed a rapid release of the loaded drug with 50 % of the drug being released in about 2 
days. Increasing β-GP or glycerol content lead to a slower release, with only about 20 % of 
the loaded drug being released after 20 days for the formulation C3-β15-G0. Of importance is 
that none of the formulations displayed burst release. To get an indication of the mechanism 
of the drug release, the cumulative release up to about 60 %, as suggested by others [30, 31], 
was fitted to the equation: 
 (1) 
where Mt is the amount of drug released at time t, M∞ is the amount of drug released at 
infinite time, k and n are both constants. The value of n is commonly taken as an indication of 
the release mechanism, where a value of 0.5 for slabs, or 0.43 for spheres suggests diffusion 
controlled (Fickian) release, while a value of 1 for slabs or 0.85 for spheres suggests 
7 
 
relaxation controlled release. Values in between indicates an anomalous release mechanism 
[30, 31]. The fit of Eq. 1 to release data suggests that the in vitro release was rather well 
described by Fickian release mechanism (see Table 1 and fit to data in Fig. 3). 
3.4. In vivo therapeutic effect and nanogel clearance 
To evaluate the in vivo performance of drug loaded nanogels, Long Evan rats, which 
spontaneously present SWDs [26, 27], were used as test subjects. The SWDs of Long Evan 
rats have been suggested to be an absence like seizure activity that is known to be suppressed 
by the antiepileptic drug ESM [26, 28, 29]. Thus, the therapeutic effect of ESM loaded 
nanogels in the chosen model was expected to give good initial indications on the feasibility 
of the nanogels for future drug delivery therapy. The rats received a 1 ml subcutaneous 
implant of the nanogel C3-β5-G5, containing 10 mg / ml ESM, and gelation at the site of 
administration was confirmed using MRI. The ESM treatment reduced the number of 
recorded SWDs to about 50 % on days 1 - 3 after injection. From day 4 the number of SWDs 
increased, reaching pre-treatment levels at days 6 - 7. In addition, the amplitude of the SWDs 
that did occur during days 2 – 3 was much less than that observed prior to treatment and 
during days at which the number of SWDs was not significantly reduced. MRI analysis 
revealed that the nanogel clearance was completed during a time period similar to the duration 
of the therapeutic effect. The clearance initially proceeded at a relatively low rate up to day 2, 
between days 2 – 5 it accelerated, leading to about 20 % of the gel remaining at day 5. At day 
7, the implanted nanogel was all but gone (Fig. 4). 
3.5. Cytotoxicity of CHC nanogels 
Since the CHC nanogels were mainly composed of water and chitosan, they were likely 
to be highly biocompatible, as reported for native thermo-gelling chitosan gels [32]. The 
cytotoxicity of different formulations of CHC nanogels was investigated by the MTT assay 
using Human retinal pigmented epithelium cells (ARPE-19). As seen in Fig. 5, only a very 
small decrease in cell viability could be detected for the nanogels with the highest β-GP and 
glycerol contents (C3-β15-G0 and C3-β5-G10), for all other investigated samples there was 
no significant difference in cell viability compared to the control. 
4. Discussion 
A novel injectable thermo-gelling nanogel with no burst release was developed based on 
combination of nanocapsules of CHC, β-GP and glycerol.  
Different formulations were investigated with regard to gelation time when transferred 
from 4 
○
C to 37 
○
C. The results presented in Table 1 revealed that the gelation time was 
strongly dependent on composition of the pre-gelling solution. In particular,  
β-GP was a prerequisite for thermo induced gelation and the gelation time was dramatically 
decreased with increasing CHC content. This reduction in gelation time is surely a result of 
more CHC macromolecules or preferably, nanocapsules aggregating or coagulating, reaching 
a continuous network in a shorter time under the same chemical environment. The formed 
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gels had a phase separated structure with micrometer sized CHC containing regions forming a 
continuous network, as seen from two photon microscopy analysis of pyrene loaded 
nanocapsules (Fig. 2c). Furthermore, the observations revealed that gelation is largely 
promoted not only by β-GP, as reported previously for native chitosan [32, 33], but also by the 
presence of glycerol. Rheological analysis revealed that CHC solutions containing glycerol 
formed harder gels than those prepared using only β-GP (supplementary material Fig. S3). 
The rheological analysis also revealed that the storage modulus of the reported gels evolved 
similarly to previous reported chitosan based thermogelling systems [6, 14, 16], forming 
relatively weak gels in comparison to systems based on synthetic thermogelling polymers [7, 
15] or in situ gelling systems that utilizes mechanisms other than thermo-gelation [15, 21]. 
The used CHC is known to exist as self-assembled nanocapsules in solution [19, 20]. 
TEM analysis of prepared and subsequently dried gels as well as SEM analysis of freeze-
dried gels revealed that nanocapsules were also present in the formed gels, as seen in Fig. 2a, 
b. Thus, the network in the nanogels was probably composed of nanocapsules connected 
through physical interactions, e.g., hydrophobic interactions and hydrogen bonds. As such, the 
CHC nanogels likely had a network structure significantly different from conventional 
chitosan-based hydrogels reported in literature where the continuous network is composed of 
polymer chains. The non-covalent nature of the network should allow for time dependent 
disintegration of the hydrogels, which would be desirable for transient implant applications. 
Indeed, after long-term incubation in SBF or DW, the bulk CHC gels were found to swell and 
slowly disintegrate (Supplementary material Fig. S4). As seen from SEM analysis of released 
gel fragments (Fig. 2d), the gels mainly disintegrated through the release of nano-sized 
fragments, in turn composed of an assembly of smaller objects, likely CHC nanocapsule 
assemblies. Given the simple disintegration route, it seemed probable that the gels could also 
disintegrate in vivo, and that the resulting nanoparticles and primary nanocapsules could be 
efficiently transported away from the remaining bulk gel.  
The fact that the CHC nanogels were composed of self-assembled CHC nanocapsules, 
which have been shown to efficiently encapsulate drugs and have extended release profiles 
[19, 20], surely suggests that the gels could be exceptionally suitable for depot drug delivery 
applications in which a sustained release with minimal burst release is desired. In vitro release 
studies revealed that in accordance with the aim of this study no burst release was observed 
for any of the formulations (Fig. 3). The fitting of Eq. 1 to data suggests, guided by previous 
works [30, 31], that the in vitro drug release from the gels was rather diffusion controlled. It 
needs to be emphasized that the lack of burst release and in some cases very slow release 
strongly indicates that the drug was indeed encapsulated in the nanocapsules, and that 
diffusion out of those are the rate limiting step. The differences in release rates between the 
formulations were probably due to different network structures in the gels and differences in 
the chemical environment in the gels. The exact reason would be interesting to investigate 
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further, but is beyond the scope of this study.  
Based on the release data and analysis the nanogels have potential for long term 
sustained release, such as drug depot formulations. The therapeutic effect of ESM was 
demonstrated in vivo utilizing Long Evans Rats as the animal model, and was found to 
coincide with the in vivo clearance of the hydrogels from the site of administration (Fig. 4). 
Apparently therapeutic drug levels were not reached until day 1, and remained until day 4, in 
contrast, for free ESM there is a rapid initial response 1 h after administration [34] and the 
effect is significantly lower already after 24 h. From the in vivo release study it can be 
concluded that the nanogels seem promising as a depot sustained release platform. However, 
further animal studies will be needed to investigate the in vivo performance of different 
nanogel compositions, using different drugs.  
Given the promising in vivo results, the cytotoxicity of the nanogels was evaluated using 
Human retinal pigmented epithelium cells. The results revealed that the all investigated 
nanogel formulations exhibited very low cytotoxicity (Fig. 5), further strengthening the 
potential of said nanogels in biomedical applications.  
5. Conclusion 
In summary, the presented nanogels display excellent properties with regard to usage as 
an injectable depot drug delivery system. The preparation procedure is very easy as CHC both 
encapsulate the drug, with reduced burst release and release rate as consequences, and is the 
gel network forming constituent. The gels display sol-gel transition when exposed to 
physiological temperature, excellent cytotoxicity data and successful usage as a depot drug 
delivery system in vivo. The gels presented in this proof of concept study displays many 
interesting properties that could be investigated in detail. In particular, future studies would be 
to develop the characterization of the in vivo performance using different gel formulations, 
animal models and drugs and to investigate the use of the nanogels in cancer therapy or other 
indications. On a more fundamental level it would be interesting to characterize the gel 
network formation during the gelation and to investigate how structure and composition 
influences properties such as in vitro drug release, mechanical properties and in vivo 
disintegration of the gels. 
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Figure legends 
Fig. 1 The concept of CHC nanogel preparation and thermo-gelling. (a) Positively charged 
nanocapsules were neutralized by glycerophosphate di-sodium salt, glycerol was added to 
improve the hardness of formed CHC nanogels. (b) CHC solution (C2-β5-G10) before and 
after thermally induced gelation. 
Fig. 2 Microscopy images of CHC gels. (a) TEM image of CHC nanogel (C3-β5-G10) dried 
after gelation. (b) SEM image showing CHC nanogel (C3-β5-G5) after freeze-drying. (c) Two 
photon microscopy image of pyrene loaded CHC nanogel network (C3-β5-G5) dimensions 
are 424x424x255 um, insert is 1-D image. (d) SEM images of gel fragments released from 
submerged nanogel (C3-β5-G10).  
Fig. 3 Cumulative drug release for (a) Different formulations loaded with ESM; C3-β5-G0 
(■),C3-β5-G5 (♦), C3-β5-G10 (●) and C3-β15-G0 (▲) Error bars indicate one standard 
deviation (n = 3). Dashed lines are fit of Eq. 1 to data with exponents (n) as seen in table 1. 
Fig. 4 Therapeutic effect and in vivo disintegration of ESM loaded, subcutaneously implanted 
CHC nanogels. (a) Typical SWDs recorded one day before injection (B1), immediately after 
injection (D0), and 2 – 7 days after injection (D2 –D7). (b) MR images of the implanted CHC 
nanogel at different times. (c) Hourly number of SWDs and remaining gel volume before and 
at given times after injection. Data presented as mean, error bars indicate one standard 
deviation (n = 5). 
Fig. 5 Cell Viability of ARPE-19 cells cultured in media containing various formulations of 
CHC nanogels. Error bars indicate one standard deviation (n = 3). 
Table 1. The n and R
2
 values for formulations used for in vitro release experiments, from fit 
of data to Eq. 1. 
Sample n R
2 
ESM-C3-β5-G0 0.56 1.0 
ESM-C3-β5-G5 0.50 0.99 
ESM-C3-β5-G10 0.38 0.98 
ESM-C3-β15-G0 0.51 1.0 
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